The Present and Future
Review Topic of the Week
Stimulating High Impact HIV-Related Cardiovascular Research: Recommendations From a Multidisciplinary NHLBI Working Group on HIV-Related Heart, Lung, and Blood Disease

https://doi.org/10.1016/j.jacc.2014.12.014Get rights and content
Under an Elsevier user license
open archive

Abstract

The clinical challenges confronting patients with human immunodeficiency virus (HIV) have shifted from acquired immunodeficiency syndrome (AIDS)-related illnesses to chronic diseases, such as coronary artery disease, chronic lung disease, and chronic anemia. With the growing burden of HIV-related heart, lung, and blood (HLB) disease, the National Heart, Lung, and Blood Institute (NHLBI) recognizes it must stimulate and support HIV-related HLB research. Because HIV offers a natural, accelerated model of common pathological processes, such as inflammation, HIV-related HLB research may yield important breakthroughs for all patients with HLB disease. This paper summarizes the cardiovascular recommendations of an NHLBI Working Group, Advancing HIV/AIDS Research in Heart, Lung, and Blood Diseases, charged with identifying scientific priorities in HIV-related HLB disease and developing recommendations to promote multidisciplinary collaboration among HIV and HLB investigators. The working group included multidisciplinary sessions, as well as HLB breakout sessions for discussion of disease-specific issues, with common themes about scientific priorities and strategies to stimulate HLB research emerging in all 3 groups.

Key Words

acquired immunodeficiency syndrome
cardiovascular disease
coronary artery disease
disease progression
inflammation
risk factors

Abbreviations and Acronyms

AIDS
acquired immunodeficiency syndrome
ART
antiretroviral therapy
CAD
coronary artery disease
CV
cardiovascular
HIV
human immunodeficiency virus
HLB
heart, lung, and blood
NHLBI
National Heart, Lung, and Blood Institute
NIH
National Institutes of Health
WG
working group

Cited by (0)

Dr. Hsue has received consulting fees from Gilead and Amgen. Dr. Ridker is listed as a coinventor on patents held by the Brigham and Women’s Hospital and licensed to Seimens and AstraZeneca relating to the use of inflammatory biomarkers in cardiovascular disease and diabetes. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.

You can also listen to this issue's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.